Abstract 259P
Background
Borderline ovarian tumor(BOT) is a peculiar type of tumor with a favorable prognosis than the malignant tumors.There remains many gaps in our knowledge of the disease that result in controversies regarding their biology and different therapeutic approaches.The study aimed to evaluate the effect of suigical staging procedures on the prognosis and pregnant outcomes in the patients with BOTs.
Methods
We performed a retrospective analysis involving BOT patients who had underwent surgical staging procedures or not in West China Second University Hospital from January 2008 to January 2015 . The recurrence free survival (RFS)and pregnant outcomes were analysed using Kaplan-Meier method and Cox regression analysis, respectively.
Results
448 patients were included in the study with a median age of 35 years and median follow-up time of 113 months.Firty-two(11.6%)patients experienced relapse with the recurrent interval 80.2 months .Four(0.9%)patients died of the disease.118(26.3%)patients had undergone staging surgery while 330(73.7%) had done not.233 patients with fertility sparing surgery(FSS)attempted to conceive and 92(39.48%) achieved pregnancy.No significant difference of fertility outcomes were observed in the stagingsurgery or not groups(P = 0.691).In univariate analyses,staging surgery was obviously associated with RFS (HR = 2.191 P = 0.005),but was not an independent prognostic factor (p = 0.600) .Furthermore,the multivariate Cox analysis revealed that FIGO advanced stage(≥stage II), positive ascitescytologic washing and laparotomy were independent prognostic factors for RFS in the total population.
Conclusions
The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes.When involved in early-stage (I),laproscope will be further rationally recommended to the patients with FSS than laparotomy.In addition, BOT patients with fertility desiring at advanced stage ,with invasive implants and bilateral tumors should choose FSS carefully.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
West China Second University Hospital,SiChuan Univeristy.
Funding
Has not received any funding.
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract